Potential diagnostic, prognostic and therapeutic implications of some new regulatory proteins in hematologic malignancies

Journal of Experimental and Clinical Cancer Research

Volumn 19, Issue 2, 2000, Pages 175-181

  Milosevic D ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

Clinical implications; Hematologic malignancies; Regulatory proteins

Indexed keywords

CD11 ANTIGEN; CD18 ANTIGEN; CD23 ANTIGEN; MONOCLONAL ANTIBODY; PROTEIN BCL 2; REGULATOR PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL DEATH; CELL PROLIFERATION; DIAGNOSTIC TEST; DISULFIDE BOND; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROGNOSIS;

ANTIGENS, CD; APOPTOSIS; CELL DIFFERENTIATION; CELL DIVISION; HLA-DR ANTIGENS; HUMANS; LEUKEMIA; LYMPHOMA; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR MARKERS, BIOLOGICAL;

EID: 1642602428     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Milošević D.: The value of immunophenotyping in the current classification of lymphoproliferative diseases. Journal of BUON 4: 289-296, 1998.
2. Milošević D., Marinković M., Jelic S., Colović M. and Spuzić I.: Reactivity of monoclonal antibodies OK-CLL (anti-CD5) with peripheral blood cells of patients with B-cell lymphoproliferative disorders. Arch. Immunol. Ther. Exp. 43 : 23-29, 1995.
3. Milošević D., Marinković M., Colović M. and Spuzić I.: CD5 antigen and M receptor as persistent immunological markers of chronic lymphocytic leukemia. Bilt. Hematol. 23 : 33-37, 1995.
4. Milošević D., Marinković M., Colović M. and Spuzić I.: Correlation of T cell marker expression and PHA induced lymphoproliferative response in treated acute leukemia patients. J. Exp. Clin. Cancer Res. 14 (1) : 11-16, 1995.
5. Timens W.: Cell adhesion molecule expression and homing of hematologic malignancies. Critical Reviews in Oncology/Hematology 19 : 111-129, 1995
6. Paloczi K.: Clinical applications of phenotypic analysis. Immunol. Today 13: A27-A28, 1992.
7. Faull R. J.: Adhesion molecules in health and disease.. Aust. N. Z. J. Med. 25 : 720-730, 1992.
8. Urbano-Ispizua A., Matutes E., Villamor N., Ribera J. M. and Rozman C.: Clinical significance of the presence of myeloid-associated antigens in acute lymphoblastic leukemia. Br. J. Haematol. 75 : 202-210, 1990.
9. Wiersma S. R., Ortega J., Sobel E. and Weinberg K. I.: Clinical importance of myeloid antigen expression in acute lymphoblastic leukemia of childhood. N. Engl. J. Med. 324: 800-806, 1991.
10. Walchner M. and Wick M.: Elevation of CD8+CD11b+Leu8- T cells is associated with the humoral immunodeficiency in myeloma patients. Clin. Exp. Immunol. 109:310-316, 1997.
11. Molica S., Dattilo A. and Alberti A.: Myelomonocytic associated antigens in B-chronic lymphocytic leukemia: analysis of clinical significance. Leukemia Lymphoma 5:139-145, 1991.
12. Kipps T. and Vaughan J. H.: Genetic influence on the levels of circulating CD5 B lymphocytes. J. Immunol. 139 : 1060-1067, 1987.
13. Tassies D., Montserrat E., Reverter J. C., Villamor N., Montserrat R. and Rozman C.: Myelomonocytic antigens in B cell Chronic lymphocytic leukemia. Leukemia Res.11: 841-848, 1995.
14. Delespesse G., Suter U., Mossolayi D., et al.: Expression, structure and function of the CD23 antigen. Adv. Immunol. 49: 149-191, 1991.
15. Punnonen J., Aversa G., Cocks B. G. et al: Interleukin-13 induces interleukin-4 independent IgG4 and IgE synthesis and CD23 expression by human B-cells. Proc. Natl. Acad. Sci. USA 90: 3730-3734, 1993.
16. Gordon J.: B-cell signalling via the C-type lectins CD23 and CD72. Immunol.Today 15 (9) : 411-417, 1994.
17. Dorfman D. M. and Pinkus G. S.: Distinction between lymphocytic and mantle cell lymphoma by immunoreactivity for CD23. Mod. Pathol. 7 : 326-330, 1994.
18. Kumar S., Gree G. A., Teruya-Feldstein J., Raffeld M. and Jaffe E. S.: Use of CD23 (Bu 38) on parafin sections in the diagnosis of small lymphocytic lymphoma and mantle cell lymphoma. Mod. Pathol. 9(9) : 925-929, 1996.
19. Segal G. H., Masih A. S., Fox A. C. et al.: CD5 expressing B cell non-Hodgkin' lymphomas with bcl-1 gene rearrangement have a relatively homogenous immunophenotype and are associated with an overall poor prognosis. Blood 85:1570-1579, 1995.
20. Matutes E., Owusu-Ankomah K., Morilla R., et al: The immunological profile of B-cell disorders and proposal of a scoring system for diagnosis of CLL. Leukemia 8:1640-1645, 1994.
21. Reinisch W., Willheim M., Hilgarth M. et al: Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia. J. Clin. Oncol. 12 : 2146-2152, 1994.
22. Knauf W. U., Langenmayer I., Ehlers B. et al: Serum levels of soluble CD23 , but not soluble CD25, predict disease progression in early stage B-cell chronic lymphocytic leukemia. Leukemia and lymphoma 27 : 523-532, 1997.
23. Van Oers M. H. J., Pals S. T., Evers L. M. et al: Expression and release of CD27 in human B-cell malignancies. Blood 82: 3430-3436, 1993.
24. Molica S., Vitelli G., Levato D. et al: CD27 in B-cell chronic leukemia. Cellular expression, serum release and correlation with other soluble molecules belonging to nerve growth factor receptors (NGFr) superfamily. Haematologica 83 (5) : 398-402, 1998.
25. Ranheim E. A., Cantwell M. J. and Kipps T. J.: Expression of CD27 and its ligand CD70 on chronic lymphocytic leukemia B cells. Blood 85 : 3556-3565, 1995.
26. Loenen W. A. M.: Editorial overwiew: CD27 and (TNFR) relatives in the immune system: their role in health and disease.. Seminars in immunology 10 : 417-422, 1998.
27. Smith C. A., Gruss H. J., Davis T. et al: CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging superfamily of cytokines with homology to TNF. Cell 73: 1349-1360, 1993.
28. Nadali G., Vinante F., Stein H. et al: Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ Anaplastic large-cell lymphoma. J. Clin. Oncol. 13 (6): 1355-1360, 1995.
29. Diehl V., Bohlen H. and Wolf J.: CD30 : Cytokine-receptor, differentiation marker or a target molecule for specific immune response? Annals of Oncol 5 : 300-302,1994.
30. Nadali G., Tavecchia L., Zanolin E. et al: Serum levels of sCD30 are elevated in the majority of untreated patients with Hodgkin's disease at high risk of unfavorable outcome. Blood 91: 3011-3016, 1998.
31. Gruiss H. J., Boiani N., Williams D. E., Armitage R. J., Smith C. A. and Goodwin R. G.: Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 83: 2045-2056, 1994.
32. Nadali G., Vinante F., Ambrosetti A. et al: Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. J. Clin. Oncol. 12 : 793-797, 1994.
33. Horie R. and Watanabe T.: CD30 : expression and function in health and disease. Seminars in Immunology 10 : 457-470, 1998.
34. Malavasi F., Funaro A., Alessio M. et al: CD38 : A multi-lineage cell activation molecule with a split personality. Int. J. Clin. Lab. Res. 22 : 73-80, 1992.
35. Medeiros L. J., Picker L. J., Horning S. J. and Warnke R. A.: Transferin receptor expression by non-Hodgkin's lymphomas. Correlation with morphological grade and survival. Cancer 61 : 1844-1851, 1988.
36. Pelosi E., Testa U., Louache F. et al: Expression of transferin receptors in phytohemagglutinin-stimulated human T-lymphocytes. Evidence for three-step model. J. Biol. Chem. 261 : 3036-3042, 1986.
37. Koubek K.: Atlas of human leukocyte antigens. Prague, 1-193, J+J 1992.
38. Glasova M., Konikova E., Staπakova J. and Babuπikova O.: The relationship of HLA-DR, CD38 and CD71 markers to activation, proliferation and differentiation of some human leukemia and lymphoma cells. Neoplasma 45(2) : 88-95, 1998.
39. Degiannis D. and Koniavitou K.: In vitro expression of activation markers and lymphocyte proliferation in response to Interleukin-12: Effect of immunossupressive agents. Transpl. Proc. 28(6): 3062-3064, 1996.
40. Ruis-Arguelles G. J. and San Miguel J. F.: Cell surface markers in multiple myeloma. Mayo. Clin. Proc. 69: 7, 684-690, 1994.
41. Omede R., Boccadoro M., Gallone G. et al: Multiple myeloma: Increased circulating lymphocytes carrying plasma cell-associated antigens as an indicator of poor survival. Blood 76 : 1370-1379, 1990.
42. Malavasi F., Funaro A., Roggero S., Horenstein A., Calosso L. and Mehta K.: Human CD38 : A glycoprotein in search of a function. Immunol. Today 15 : 95-97, 1994.
43. Escribano I., Ockueteau M., Almeida J., Orfao A. and San Miguel J. F.: Expression of the c-kit (CD117) molecule in normal and malignant hematopoiesis. Leukemia and lymphoma 30;459-466, 1998.
44. Macedo A., Orfao A., Martinez A. et al: Immunophenotype of c-kit cells in normal human bone marrow : Implications for the detection of minimal residual disease in AML. Br. J. Haematol. 89 : 338-341, 1995.
45. Di Giuseppe J. A., Le Beau P., Augenbraun J. and Borowitz M. J.: Multiparameter Flow-cytometric analysis of Bcl-2 and Fas expression in normal and neoplastic hematopoiesis. Amer. J. Clin. Pathol. 106 (3) : 345-351, 1996.
46. Robertson M. J., Manley T. J., Pichert G. et al: Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells. Leukemia and Lymphoma 17:51-61, 1995.
47. Shima Y., Nishimoto N., Yoshizaki K. and Kishimoto T.: Fas antigen/APO-1 (CD95) expression on myeloma cells. Leukemia and lymphoma 23 : 521-531, 1996.
48. Anthony R. S., Mc Kelvie N. D., Craig J. I. O. and Parker A. C.: Fas antigen (CD95) expression in peripheral blood progenitor cells from patients with leukemia and lymphoma. Leukemia and lymphoma 30 : 449-458, 1998.
49. Cohen P. L. and Eisenberg R. A.: Lpr and gld : single gene models of systemic autoimmunity and lymphoproliferative disease. Annu. Rev. Immunol. 9 : 243-249, 1991.
50. Rieux-Laucat F., Le Diest, Hivroz C. et al: Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268 : 1347-1349,. 1995.
51. Takano Y., Saegusa M., Masuda M., Mikami T. and Okayasu I.: Apoptosis, proliferative activity and Bcl-2 expression in Epstein-Barr-virus-positive non-Hodgkin's lymphomas. J. Cancer. Res. Clin. Oncol. 123 : 395-401, 1997.
52. Tsujimoto Y., Ikegami N. and Crose C. M.: Characterisation of the protein product of Bcl-2, the gene involved in human follicular lymphoma. Oncogene 2 : 3-7, 1987.
53. Soini Y., Raunio H. and Paakko P.: High-grade malignant non-Hodgkin's lymphomas differ from low-grade lymphomas in the extent of apoptosis and their expression of Bcl-2, mcl-1, bax and p53. Tumor Biol. 19:176-185, 1998.
54. Vitolo U., Gaidano G., Botto B. et al: Rearrangements of Bcl-6, Bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: clinical relevance in 71 patients. Annals of Oncology 9 : 55-61, 1998.
55. Wang T., Lasota J., Hanan C. A. and Miettinen M: Bcl-2 oncoprotein is widespread in lymphoid tissue and lymphomas but its differential expression in benign versus malignant follicles and monocytoid B-cell proliferations is of diagnostic value. APMIS 103 : 655-662, 1995.
56. Kotani T., Aratake Y., Kondo S., Tamura K. and Ohtaki S.: Expression of functional Fas antigen in adult T-cell leukemia. Leukemia Research 18 : 305-310, 1994.
57. Min Y. H., Lee S., Lee J. W., Chong S. Y., Hahn J. S. and Ko Y. W.: Expression of Fas antigen in acute myeloid leukemia is associated with therapeutic response to chemotherapy. Brit. J. Haematol. 93 : 928-930, 1996.
58. Shima Y., Nishimoto N., Ogata A., Fujii Y., Yoshizaki K. and Kishimoto T.: Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood 85 : 757-764, 1994.
59. Kvalheim G., Manara M. Y., Hoifodt H. et al: Triggering of the APO-1/Fas antigen (CD95) selectively kiles leukemic cells without compromising hematopoietic stem cells: a novel strategy for tumor cell purging of autografts. Blood 84 : S1, 570a, 1994.